ES3063371T3 - Topical ophthalmological compositions - Google Patents
Topical ophthalmological compositionsInfo
- Publication number
- ES3063371T3 ES3063371T3 ES21878639T ES21878639T ES3063371T3 ES 3063371 T3 ES3063371 T3 ES 3063371T3 ES 21878639 T ES21878639 T ES 21878639T ES 21878639 T ES21878639 T ES 21878639T ES 3063371 T3 ES3063371 T3 ES 3063371T3
- Authority
- ES
- Spain
- Prior art keywords
- topical ophthalmological
- ophthalmological compositions
- compositions
- topical
- ophthalmological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089263P | 2020-10-08 | 2020-10-08 | |
| US17/317,551 US11191751B1 (en) | 2020-10-08 | 2021-05-11 | Topical ophthalmological atropine free base compositions |
| PCT/US2021/054221 WO2022076852A1 (en) | 2020-10-08 | 2021-10-08 | Topical ophthalmological compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3063371T3 true ES3063371T3 (en) | 2026-04-16 |
Family
ID=78818588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21878639T Active ES3063371T3 (en) | 2020-10-08 | 2021-10-08 | Topical ophthalmological compositions |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11191751B1 (https=) |
| EP (2) | EP4225284B1 (https=) |
| JP (1) | JP2023544853A (https=) |
| KR (1) | KR20230084190A (https=) |
| CN (1) | CN116390714A (https=) |
| AU (1) | AU2021359003A1 (https=) |
| BR (1) | BR112023006371A2 (https=) |
| CA (1) | CA3193940A1 (https=) |
| ES (1) | ES3063371T3 (https=) |
| MX (1) | MX2023004065A (https=) |
| WO (1) | WO2022076852A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10251875B2 (en) | 2017-05-11 | 2019-04-09 | Nevakar Inc. | Atropine pharmaceutical compositions |
| US11191751B1 (en) * | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
| MX2023009091A (es) | 2021-02-03 | 2023-08-09 | Ads Therapeutics Llc | Composiciones oftalmologicas topicas. |
| KR20240136369A (ko) * | 2022-01-21 | 2024-09-13 | 에이디에스 테라퓨틱스 엘엘씨 | 8-메틸-8-아자비사이클로[3.2.1] 옥탄-3-일의 에스테르 3-하이드록시-2-페닐프로파노에이트 |
| JP2025541009A (ja) | 2022-12-23 | 2025-12-17 | ノバリック ゲーエムベーハー | ヒヨスチアミンを含む半フッ化アルカン組成物 |
| CN117982412B (zh) * | 2024-02-04 | 2024-09-17 | 济川(上海)医学科技有限公司 | 一种醋克利定眼用组合物及其药物制剂和用途 |
| WO2025259674A1 (en) * | 2024-06-11 | 2025-12-18 | Ads Therapeutics Llc | Compositions and methods for delivery of pharmaceutical actives |
| WO2025264886A1 (en) * | 2024-06-19 | 2025-12-26 | Btv Holding, Llc | Ophthalmic preparations and methods of use |
| WO2026011139A1 (en) * | 2024-07-05 | 2026-01-08 | Ads Therapeutics Llc | Transient receptor potential melastatin 8 agonist-containing ocular conditions and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070254914A1 (en) * | 2006-05-01 | 2007-11-01 | Non-Profit Organization Chang Gung Memorial Hospital | Low-concentration atropine solution for preventing myopia progression and preparing method thereof |
| EP2335735A1 (en) * | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| CN102526051A (zh) * | 2012-03-09 | 2012-07-04 | 哈尔滨医科大学 | 一种治疗真菌性角膜炎的眼药膏 |
| CN113679699B (zh) * | 2012-09-12 | 2022-10-28 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| US9421199B2 (en) * | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| US11510931B2 (en) * | 2016-09-28 | 2022-11-29 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
| AU2017333420A1 (en) * | 2016-09-28 | 2019-04-04 | Novaliq Gmbh | Compositions comprising a cannabinoid receptor binding ligand |
| BR112019012568A2 (pt) * | 2016-12-22 | 2019-11-26 | Novaliq Gmbh | composições compreendendo tacrolimus para o tratamento de doenças intraoculares inflamatórias |
| WO2019068763A1 (en) * | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | OPHTHALMIC COMPOSITIONS COMPRISING F6H8 |
| TW201932104A (zh) * | 2017-11-03 | 2019-08-16 | 澳大利亞商布萊恩荷登視覺協會 | 用於控制及/或降低近視進展之醫藥組合物 |
| SG11202102820VA (en) * | 2018-10-12 | 2021-04-29 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| WO2020152046A1 (en) * | 2019-01-21 | 2020-07-30 | Novaliq Gmbh | Pharmaceutical composition for the treatment of ocular neovascularisation |
| CA3128224A1 (en) * | 2019-02-01 | 2020-08-06 | Aerie Pharmaceuticals, Inc. | Compounds, compositions and methods for treatment of myopia |
| US11191751B1 (en) * | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
| MX2023009091A (es) * | 2021-02-03 | 2023-08-09 | Ads Therapeutics Llc | Composiciones oftalmologicas topicas. |
-
2021
- 2021-05-11 US US17/317,551 patent/US11191751B1/en active Active
- 2021-10-08 CN CN202180068863.0A patent/CN116390714A/zh active Pending
- 2021-10-08 WO PCT/US2021/054221 patent/WO2022076852A1/en not_active Ceased
- 2021-10-08 ES ES21878639T patent/ES3063371T3/es active Active
- 2021-10-08 EP EP21878639.0A patent/EP4225284B1/en active Active
- 2021-10-08 MX MX2023004065A patent/MX2023004065A/es unknown
- 2021-10-08 US US18/029,323 patent/US20230355594A1/en active Pending
- 2021-10-08 EP EP25217226.7A patent/EP4706766A2/en active Pending
- 2021-10-08 KR KR1020237013835A patent/KR20230084190A/ko active Pending
- 2021-10-08 CA CA3193940A patent/CA3193940A1/en active Pending
- 2021-10-08 BR BR112023006371A patent/BR112023006371A2/pt unknown
- 2021-10-08 AU AU2021359003A patent/AU2021359003A1/en active Pending
- 2021-10-08 JP JP2023521587A patent/JP2023544853A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116390714A (zh) | 2023-07-04 |
| US20230355594A1 (en) | 2023-11-09 |
| EP4706766A2 (en) | 2026-03-11 |
| CA3193940A1 (en) | 2022-04-14 |
| EP4225284B1 (en) | 2025-11-26 |
| WO2022076852A1 (en) | 2022-04-14 |
| AU2021359003A1 (en) | 2023-05-04 |
| US11191751B1 (en) | 2021-12-07 |
| EP4225284C0 (en) | 2025-11-26 |
| KR20230084190A (ko) | 2023-06-12 |
| BR112023006371A2 (pt) | 2023-05-09 |
| JP2023544853A (ja) | 2023-10-25 |
| EP4225284A1 (en) | 2023-08-16 |
| MX2023004065A (es) | 2023-05-03 |
| AU2021359003A9 (en) | 2024-06-13 |
| EP4225284A4 (en) | 2024-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3063371T3 (en) | Topical ophthalmological compositions | |
| EP4288151A4 (en) | Topical ophthalmological compositions | |
| ZA202403158B (en) | Compositions | |
| GB202013432D0 (en) | Compositions | |
| PL4065661T3 (pl) | Kompozycje | |
| GB202011605D0 (en) | Topical formulation | |
| GB202015836D0 (en) | Compositions | |
| GB202105461D0 (en) | Compositions | |
| GB202102704D0 (en) | Compositions | |
| GB202011581D0 (en) | Anti-microbial compositions | |
| GB2610026B (en) | Compositions | |
| HK40096308A (en) | Topical ophthalmological compositions | |
| GB202002048D0 (en) | Compositions | |
| GB202117631D0 (en) | Topical compositions | |
| GB202015404D0 (en) | Topical composition | |
| GB202107169D0 (en) | Therapeutic compositions | |
| GB202012836D0 (en) | Topical composition | |
| HK40045846B (en) | Therapeutic compositions | |
| GB202010639D0 (en) | Therapeutic compositions | |
| HK40085875A (en) | Therapeutic compositions | |
| GB202106934D0 (en) | Topical formulation | |
| ZA202210764B (en) | Compositions | |
| GB202118081D0 (en) | Compositions | |
| GB202117074D0 (en) | Compositions | |
| GB202116861D0 (en) | Compositions |